Cargando…

Hematologic side effects of immune checkpoint inhibitor with or without chemotherapy in patients with advanced and metastatic gastrointestinal cancer: A systematic review and network meta-analysis of phase 3 trials

Background: The regimens of immune checkpoint inhibitors (ICIs) alone or with chemotherapy are emerging as systemic therapy for patients with advanced and metastatic gastrointestinal cancers. However, the risk of treatment-related hematologic toxicity stays unclear. Methods: We enrolled in phase 3 r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Jingyi, Xie, Ruiyang, Zhang, Zhuo, Liu, Qianxin, Xiang, Qian, Cui, Yimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073573/ https://www.ncbi.nlm.nih.gov/pubmed/37033653 http://dx.doi.org/10.3389/fphar.2023.1163971

Ejemplares similares

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects
por: Brown, James, et al.
Publicado: (2022)

Photodynamic therapy in combination with immune checkpoint inhibitors plus chemotherapy for first-line treatment in advanced or metastatic gastric or gastroesophageal junction cancer: A phase 2–3 clinical trial protocol
por: Yu, Yang, et al.
Publicado: (2023)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer
por: Pang, Xiaocong, et al.
Publicado: (2019)

Advances in Achieving Opioid Analgesia Without Side Effects
por: Machelska, Halina, et al.
Publicado: (2018)

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis
por: Liu, Zijing, et al.
Publicado: (2023)

Herbal medicines for the treatment of cancer chemotherapy-induced side effects
por: Ohnishi, Shunsuke, et al.
Publicado: (2015)

Natural Product Interventions for Chemotherapy and Radiotherapy-Induced Side Effects
por: Zhang, Qing-Yu, et al.
Publicado: (2018)

Preventive Effect of Curcumin Against Chemotherapy-Induced Side-Effects
por: Liu, Zhijun, et al.
Publicado: (2018)

Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective
por: Chen, Dongmei, et al.
Publicado: (2018)

Pharmacogenetics–Based Preliminary Algorithm to Predict the Incidence of Infection in Patients Receiving Cytotoxic Chemotherapy for Hematological Malignancies: A Discovery Cohort
por: Martinez, Matias F., et al.
Publicado: (2021)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Jin, Ting, et al.
Publicado: (2020)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
por: Liu, Xiangxing, et al.
Publicado: (2022)

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase
por: Yue, Bei, et al.
Publicado: (2021)

Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival
por: Wang, Peng-Fei, et al.
Publicado: (2018)

Multi-Component Herbal Products in the Prevention and Treatment of Chemotherapy-Associated Toxicity and Side Effects: A Review on Experimental and Clinical Evidences
por: Fu, Bowen, et al.
Publicado: (2018)

ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: Riera, Pau, et al.
Publicado: (2020)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
por: Pei, Zhengda, et al.
Publicado: (2023)

Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma
por: Waninger, Jessica J., et al.
Publicado: (2022)

PROTACs: Walking through hematological malignancies
por: Bou Malhab, Lara J., et al.
Publicado: (2023)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
por: Yan, Xinyu, et al.
Publicado: (2018)

Co-expression and prognosis analyses of GLUT1–4 and RB1 in breast cancer
por: Zhang, Xiaodan, et al.
Publicado: (2021)

Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2019)

CYP2J2(∗)7 Genotype Predicts Risk of Chemotherapy-Induced Hematologic Toxicity and Reduced Relative Dose Intensity in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis
por: Qu, Hong-Chen, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Sintilimab Combined with Chemotherapy Versus Chemotherapy Alone as the First-Line Treatment for Advanced Esophageal Cancer
por: Ye, Zhuo-Miao, et al.
Publicado: (2022)

Rapamycin is Effective for Upper but not for Lower Gastrointestinal Crohn’s Disease-Related Stricture: A Pilot Study
por: Zhong, Min, et al.
Publicado: (2021)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
por: Liu, Wenjie, et al.
Publicado: (2023)

Corrigendum: Abscopal Effects in Radio-Immunotherapy—Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition
por: Trommer, Maike, et al.
Publicado: (2020)

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients
por: De Mattia, Elena, et al.
Publicado: (2018)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Link between diet and chemotherapy related gastrointestinal side effects
por: Mardas, Marcin, et al.
Publicado: (2017)

Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers
por: Hu, Jiyun, et al.
Publicado: (2023)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Releasing the spindle assembly checkpoint without tension
por: McEwen, Bruce F., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_16iorab3cqmkdhmpk917u9qppr